Who Paid My Doc
Daniel Berg
Geriatric Medicine New Prague, MN Medical Doctor
NPI 1659362069 CMS profile 865454
1400 1St St Ne, New Prague, MN 56071
General payments
$245
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Berg of New Prague, MN is reported in the CMS Open Payments database as having received $245 across 14 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 54th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $104 | 5 | |
| 2024 | General | $19 | 1 | |
| 2023 | General | $35 | 2 | |
| 2020 | General | $27 | 1 | |
| 2019 | General | $60 | 5 |
Beside peers
- Daniel Berg
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Daniel Berg were reported at $104. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.
Show as a table
| Year | Daniel Berg | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $60 | $96 | $28–$339 | $163 |
| 2020 | $27 | $99 | $28–$262 | $114 |
| 2021 | $0 | $94 | $27–$318 | $132 |
| 2022 | $0 | $103 | $34–$338 | $149 |
| 2023 | $35 | $109 | $39–$320 | $160 |
| 2024 | $19 | $125 | $36–$371 | $164 |
| 2025 | $104 | $120 | $37–$350 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 152 drugsPart D claims
8,297
Drug cost
$690,554
Branded share of claims
18.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Zemaira Alpha-1-Proteinase Inhibitor | Brand | 15 | $182,720 | |
| Eliquis Apixaban | Brand | 134 | $146,379 | |
| Jardiance Empagliflozin | Brand | 49 | $60,378 | |
| Ozempic Semaglutide | Brand | 46 | $42,388 | |
| Xarelto Rivaroxaban | Brand | 42 | $35,375 | |
| Trulicity Dulaglutide | Brand | 22 | $21,681 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 19 | $19,971 | |
| Myrbetriq Mirabegron | Brand | 13 | $15,533 | |
| Repatha Sureclick Evolocumab | Brand | 25 | $14,673 | |
| Mounjaro Tirzepatide | Brand | 13 | $13,246 |
The 10 drugs with the highest cost, of 152 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 109 billing codesPaid by Medicare
$79,510
Medicare patients
181
Services billed
2,963
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 30% | |
| Diabetes | 24% | |
| Ischemic heart disease | 19% | |
| Atrial fibrillation | 18% | |
| Heart failure | 16% | |
| Chronic kidney disease | 16% | |
| Cancer | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90653 | Office | 27 | 27 | $2,186 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 25 | 37 | $29 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 13 | 57 | $20 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
14 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Geriatric Medicine in Minnesota
Clemencia Rasquinha
Geriatric Medicine · Golden Valley, MN
Michael Orourke
Geriatric Medicine · New Prague, MN
Asma Khalid
Geriatric Medicine · Le Sueur, MN
Scott Fairbairn
Geriatric Medicine · Minneapolis, MN
Nicholas Schneeman
Geriatric Medicine · Robbinsdale, MN
Syed Hasan
Geriatric Medicine · Maplewood, MN
Related records
Geriatric Medicine in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.